Is PTPI or BPTH more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% Bio-Path N/A -2,842.40% -337.48%

Which has stronger valuation & earnings, BPTH or VINC?

Vincerx Pharma is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is BPTH or VINC more profitable?

Vincerx Pharma's return on equity of -248.33% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% Vincerx Pharma N/A -248.33% -132.73%

Is SISI or BPTH more profitable?

Bio-Path has a net margin of 0.00% compared to Shineco's net margin of -380.55%. Shineco's return on equity of -79.89% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Shineco -380.55% -79.89% -33.01% Bio-Path N/A -2,842.40% -337.48%

Do analysts rate BPTH or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, BPTH or CDT?

Bio-Path is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A CDT Equity N/A N/A -$39.22M -$83.86 thousand N/A

Is BPTH or CDT more profitable?

CDT Equity's return on equity of -72.25% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% CDT Equity N/A -72.25% -55.44%

Is BPTH or CARM more profitable?

Bio-Path has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% Carisma Therapeutics -254.28% N/A -192.17%

Bio-Path (BPTH) Competitors

$0.0006 +0.00 (+100.00%)

As of 01:43 PM Eastern

Compare

BPTH vs. PTPI, VINC, SISI, CDT, and CARM

Should you buy Bio-Path stock or one of its competitors? Bio-Path's main competitors and comparable companies include Petros Pharmaceuticals (PTPI), Vincerx Pharma (VINC), Shineco (SISI), CDT Equity (CDT), and Carisma Therapeutics (CARM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bio-Path compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Bio-Path	Neutral

Petros Pharmaceuticals has higher revenue and earnings than Bio-Path. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.02	-$8.16M	-$0.36	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Petros Pharmaceuticals has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.44, suggesting that its stock price is 144% less volatile than the broader market.

Petros Pharmaceuticals' return on equity of -78.22% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Bio-Path	N/A	-2,842.40%	-337.48%

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Petros Pharmaceuticals beats Bio-Path on 8 of the 9 factors compared between the two stocks.

How does Bio-Path compare to Vincerx Pharma?

Bio-Path (NASDAQ:BPTH) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Bio-Path has a beta of -0.44, meaning that its share price is 144% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Vincerx Pharma is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
Vincerx Pharma	Neutral

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vincerx Pharma's return on equity of -248.33% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Vincerx Pharma	N/A	-248.33%	-132.73%

Summary

Vincerx Pharma beats Bio-Path on 5 of the 8 factors compared between the two stocks.

How does Bio-Path compare to Shineco?

Shineco (NASDAQ:SISI) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

4.1% of Shineco shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 0.0% of Shineco shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Shineco's average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company	Overall Sentiment
Shineco	Neutral
Bio-Path	Neutral

Shineco has a beta of -1.76, suggesting that its share price is 276% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.44, suggesting that its share price is 144% less volatile than the broader market.

Bio-Path has lower revenue, but higher earnings than Shineco. Bio-Path is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shineco	$9.60M	0.00	-$22.45M	-$204.00	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Bio-Path has a net margin of 0.00% compared to Shineco's net margin of -380.55%. Shineco's return on equity of -79.89% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shineco	-380.55%	-79.89%	-33.01%
Bio-Path	N/A	-2,842.40%	-337.48%

Summary

Bio-Path beats Shineco on 6 of the 10 factors compared between the two stocks.

How does Bio-Path compare to CDT Equity?

Bio-Path (NASDAQ:BPTH) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Bio-Path has a beta of -0.44, meaning that its share price is 144% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

Bio-Path is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
CDT Equity	N/A	N/A	-$39.22M	-$83.86 thousand	N/A

In the previous week, CDT Equity had 6 more articles in the media than Bio-Path. MarketBeat recorded 6 mentions for CDT Equity and 0 mentions for Bio-Path. CDT Equity's average media sentiment score of 0.99 beat Bio-Path's score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
Bio-Path	Neutral
CDT Equity	Positive

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 7.3% of CDT Equity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CDT Equity's return on equity of -72.25% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
CDT Equity	N/A	-72.25%	-55.44%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CDT Equity beats Bio-Path on 7 of the 10 factors compared between the two stocks.

How does Bio-Path compare to Carisma Therapeutics?

Bio-Path (NASDAQ:BPTH) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
Carisma Therapeutics	Neutral

Bio-Path has higher earnings, but lower revenue than Carisma Therapeutics. Bio-Path is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

Bio-Path has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Bio-Path has a beta of -0.44, meaning that its share price is 144% less volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.6, meaning that its share price is 1,060% less volatile than the broader market.

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Carisma Therapeutics beats Bio-Path on 7 of the 10 factors compared between the two stocks.

Get Bio-Path News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTH vs. The Competition

Export

Metric	Bio-Path	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32K	$12.13B	$7.18B	$13.18B
Dividend Yield	N/A	2.63%	2.52%	19.60%
P/E Ratio	0.00	626.67	195.97	18.94
Price / Sales	N/A	746.64	564.50	78.56
Price / Cash	N/A	84.08	76.68	52.75
Price / Book	0.00	9.15	10.51	5.92
Net Income	-$16.08M	$2.82B	$3.50B	$380.90M
7 Day Performance	N/A	-4.55%	-4.32%	-4.38%
1 Month Performance	N/A	-8.50%	-8.64%	-7.25%
1 Year Performance	N/A	-6.15%	2.05%	-4.95%

Bio-Path Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTH Bio-Path	N/A	$0.00 +100.0%	N/A	-99.6%	$32K	N/A	N/A	10	Gap Down
PTPI Petros Pharmaceuticals	N/A	$0.00 -8.3%	N/A	-85.8%	$103K	$5.11M	N/A	20	Gap Down
VINC Vincerx Pharma	N/A	$0.02 flat	N/A	N/A	$79K	N/A	N/A	60
SISI Shineco	N/A	$0.11 flat	N/A	-88.3%	$44K	$9.60M	N/A	119
CDT CDT Equity	1.0233 of 5 stars	$0.83 -10.5%	N/A	-100.0%	$26K	N/A	N/A	4	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTH) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Path (BPTH) Competitors

BPTH vs. PTPI, VINC, SISI, CDT, and CARM

How does Bio-Path compare to Petros Pharmaceuticals?

Summary

How does Bio-Path compare to Vincerx Pharma?

Summary

How does Bio-Path compare to Shineco?

Summary

How does Bio-Path compare to CDT Equity?

Summary

How does Bio-Path compare to Carisma Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Path (BPTH) Competitors

BPTH vs. PTPI, VINC, SISI, CDT, and CARM

How does Bio-Path compare to Petros Pharmaceuticals?

Does the media favor PTPI or BPTH?

Which has preferable valuation and earnings, PTPI or BPTH?

Which has more risk & volatility, PTPI or BPTH?

Is PTPI or BPTH more profitable?

Do insiders & institutionals believe in PTPI or BPTH?

Summary

How does Bio-Path compare to Vincerx Pharma?

Which has more risk & volatility, BPTH or VINC?

Which has stronger valuation & earnings, BPTH or VINC?

Does the media favor BPTH or VINC?

Do institutionals & insiders hold more shares of BPTH or VINC?

Is BPTH or VINC more profitable?

Summary

How does Bio-Path compare to Shineco?

Do institutionals & insiders hold more shares of SISI or BPTH?

Does the media prefer SISI or BPTH?

Which has more risk & volatility, SISI or BPTH?

Which has better earnings & valuation, SISI or BPTH?

Is SISI or BPTH more profitable?

Summary

How does Bio-Path compare to CDT Equity?

Which has more risk and volatility, BPTH or CDT?

Which has higher valuation & earnings, BPTH or CDT?

Does the media refer more to BPTH or CDT?

Do institutionals and insiders have more ownership in BPTH or CDT?

Is BPTH or CDT more profitable?

Do analysts rate BPTH or CDT?

Summary

How does Bio-Path compare to Carisma Therapeutics?

Does the media refer more to BPTH or CARM?

Which has stronger valuation & earnings, BPTH or CARM?

Is BPTH or CARM more profitable?

Which has more risk & volatility, BPTH or CARM?

Do institutionals and insiders have more ownership in BPTH or CARM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools